Lymph Node Profile of Sentinel and Axillary Lymph Nodes

<p>Mean and standard error of CD4 and CD8 T cell, CD1a dendritic cell populations as percent of lymph node, and CD4:CD8 cell ratio are shown for (A) SLN (<i>n</i> = 29), ALN (<i>n</i> = 29), and control lymph nodes (<i>n</i> = 10); (E) tumor-involved ALNs (<i>n</i> = 9), tumor-free ALNs (<i>n</i> = 7) from patients with a positive ALND, tumor-free ALNs from patients with a negative ALND (<i>n</i> = 13), and controls (<i>n</i> = 10); (I) SLNs and ALNs stratified by disease recurrence during 5 y of follow-up (11 of 29 with recurrent disease); (L) tumor-involved ALNs stratified by disease recurrence (<i>n</i> = 9); (M) tumor-free ALNs from patients with a positive ALND stratified by disease recurrence (<i>n</i> = 7); and (N) tumor-free ALNs from patients with a negative ALND stratified by disease recurrence (<i>n</i> = 13). Representative 200× images of lymphocyte population (brown staining) and infiltrating tumor (purple staining) by IHC, including CD8 T cells in (B) SLNs, (C) ALNs, and (D) controls; (F) CD4 T cells in tumor-involved ALNs, (G) tumor-free ALNs from patients with a positive ALND, (H) tumor-free ALNs from patients with a negative ALND; and (J) CD1a dendritic cells in ALNs from patients disease-free versus (K) patients who developed recurrence.